Penumbra Inc reports results for the quarter ended June 30 - Earnings Summary
Penumbra Inc reports results for the quarter ended June 30 - Earnings Summary
Penumbra Inc PEN.N reported quarterly adjusted earnings of 88 cents per share for the quarter ended June 30, higher than the same quarter last year, when the company reported EPS of 86 cents. The mean expectation of seventeen analysts for the quarter was for earnings of $1.19 per share. Wall Street expected results to range from $1.05 to $1.27 per share.
Revenue rose 14.9% to $390.05 million from a year ago; analysts expected $389.01 million.
Penumbra Inc's reported EPS for the quarter was 88 cents.
The company reported quarterly net income of $34.81 million.
Penumbra Inc shares had risen by 1.3% this quarter and gained 2.9% so far this year.
FORECAST CHANGES
The mean earnings estimate of analysts had fallen by about 0.7% in the last three months.
In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.
RECOMMENDATIONS
The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 3 "strong buy" or "buy," 13 "hold" and no "sell" or "strong sell." The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy."
Wall Street's median 12-month price target for Penumbra Inc is $374.00, about 14.5% above its last closing price of $319.83
This summary was machine generated from LSEG data July 31 at 06:21 a.m. UTC. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
QUARTER ENDING | ESTIMATE | ACTUAL | BEAT, MET, MISSED |
Jun. 30 2026 | 1.19 | 0.88 | Missed |
Mar. 31 2026 | 1.08 | 0.82 | Missed |
Dec. 31 2025 | 1.11 | 1.18 | Beat |
Sep. 30 2025 | 0.92 | 0.97 | Beat |
Recent news on Penumbra
See all newsPenumbra Inc reports results for the quarter ended June 30 - Earnings Summary
Penumbra Q2 revenue slightly beats estimates, helped by product segment increase
Brief: Penumbra Q2 Revenue USD 390.046 Million Vs. IBES Estimate USD 389 Million
Factbox: Major deals involving US drugmakers and biotechs over the past decade
Factbox: Major deals involving US drugmakers and biotechs over the past decade